Pharmaceuticals
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is commercially available in China and is under rev...
2022-07-27 07:00
4501
Sustainable Manufacturing Practices: The Key to Mitigating Antimicrobial Resistance
JAKARTA, Indonesia, July 26, 2022 /PRNewswire/ -- Centrient Pharmaceuticals, a global business-to-business leader in sustainable, enzymatic antibiotics manufacturing, in partnership with Menjangan Sakti, a trader of pharmaceutical raw materials inIndonesia, organized a workshop on 'Sustainability...
2022-07-26 21:45
2799
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
* Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents inJapan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d...
2022-07-26 20:05
3345
Henlius HANQUYOU Received TGA Approval in Australia
SHANGHAI, July 26, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner Cipla Limited ("Cipla") has received the relevant registration certificates from the Therapeutic Goods Administration ofAustralia ("TGA") for the approval of Henlius' sel...
2022-07-26 18:03
4890
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
* All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported * The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all H...
2022-07-26 17:04
3252
Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has received regulatory clearance from t...
2022-07-26 16:58
3713
Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong
Singapore-based diagnostics developer INEX Innovate brings The Chinese University of Hong Kong together to further research work on LEXI®, INEX's fetal cell based non-invasive pre-natal diagnostics technology. SINGAPORE, July 26, 2022 /PRNewswire/ -- Singapore-based diagnostics developer and med...
2022-07-26 08:30
3854
CSafe Global Continues Investment in Cell and Gene Therapy Solutions with Addition of New Portfolio President
Amy DuRoss joins CSafe Global as President, Cell & Gene Therapy to drive innovation and solution development MONROE, Ohio, July 26, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled shipping solutions for the transport of life-enhancing pharmaceuticals, announced...
2022-07-26 03:35
4377
Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program
SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022
/PRNewswire/ --Ascentage Pharma
2022-07-25 21:59
3188
Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA
HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...
2022-07-25 18:47
2852
Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
* Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues * Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neu...
2022-07-25 12:30
4464
US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL
* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) * The open label trial will evaluate efficacy and dose ranging in patients with advanced or metasta...
2022-07-25 07:09
3617
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...
2022-07-22 07:59
3127
Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises"
SHENZHEN, China, July 21, 2022 /PRNewswire/ -- On 12 July 2022, Menet held the award ceremony of the "Annual Top 100 China's Pharmaceutical Entreprises in 2021", in which 5 sub-lists of the pharmaceutical industries had been announced. This event showcased the professionalism and influence of the...
2022-07-21 22:32
4869
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) inMay 2022 – NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopha...
2022-07-21 21:25
4583
Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 June 2022. All figures are in AUD$ unless otherwise stated. All fi...
2022-07-21 08:34
3625
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjec...
2022-07-21 08:00
2378
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 * First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach$6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean p...
2022-07-20 21:00
2375
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIRALEZE™ is a broad-spectrum barrier nasal spray, developed ...
2022-07-20 17:45
2793
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SAN FRANCISCO, ROCKVILLE, Md. and SUZHOU, China, July 20, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ...
2022-07-20 08:00
4020
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Taishin International Bank Opens Flagship Private Banking Branch in Southern Taiwan
[Picked up by 270 media titles]
2026-10-23 19:08
Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
35308
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
33878
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
32717
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
27601
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
2026-10-21 15:00
15644